Clinical Research Workshop, Part 2B, Breakout Sessions: Recompensation in Alcohol-Associated Liver Disease—Predictive Factors, Management, and Gaps in Knowledge for Future Research

Nov 08 2026
Convention Center: Bluebird Ballroom 2DEF
3:45 PM - 4:45 PM
CE Credits CE Credits

Description

This workshop highlights the evolving landscape of cirrhosis diagnosis and management, and explores how these changes are reshaping clinical research. Faculty challenge the traditional approaches to hepatocellular carcinoma (HCC) screening, and portal hypertension assessment and management. Presenters discuss the evolving concept of cirrhosis recompensation with a focus on implications for clinical trial design, end points, and patient stratification. Faculty provide a forward-looking view of cirrhosis research and address key research questions that need to be addressed in the near future. The workshop includes 3 breakout sessions where attendees have the opportunity to interact with experts in smaller groups to discuss clinical research topics of interest, including: (1) noninvasive tools for the management of portal hypertension; (2) recompensation in alcohol-associated liver disease; and (3) the future of HCC screening.

Presentations

3:45 PM - 4:10 PM
Convention Center - Bluebird Ballroom 2DEF

Breakout Session B: Recompensation in Alcohol-Associated Liver Disease—Predictive Factors, Management, and Gaps in Knowledge for Future Research

Allison J Kwong, MD | Presenter
4:10 PM - 4:35 PM
Convention Center - Bluebird Ballroom 2DEF

Breakout Session B: Recompensation in Alcohol-Associated Liver Disease—Predictive Factors, Management, and Gaps in Knowledge for Future Research

Juan Pablo Arab, MD, FRCPC | Presenter

Objectives

  • Evaluate research in emerging nonimage-based strategies for hepatocellular carcinomaincluding circulating biomarkers and composite risk scoresand assess their potential clinical role.
  • Apply updated Baveno VIII criteria to assessment and management of portal hypertension with implications for patient stratification, end point selection, and eligibility criteria for clinical trials.
  • Define recompensation in cirrhosis and identify unresolved research questions relating to prognosis, reversibility, and therapies.
  • Appraise future directions in cirrhosis research including priority research questions in 2026 and beyond.